Dexamethasone Use in Head and Neck Cancer Patients

Introduction to Dexamethasone Dosage

The recommended dexamethasone oral solution dosage for head and neck cancer patients receiving radiation therapy is 4 mg orally once daily before radiation therapy sessions, with an additional dose on the day after each radiation therapy if no radiation is planned for that day, as suggested by clinical guidelines 1, 2

For patients with a low emetic risk (10-30% risk of emesis), the standard dosage is 4 mg oral or IV dexamethasone 1
The standard dosage for head and neck cancer patients is 4 mg oral or IV dexamethasone, which can be administered once daily on days of radiation therapy and on the day after each radiation therapy session if no radiation is planned 1, 2

The administration schedule for dexamethasone in head and neck cancer patients includes once daily dosing on days of radiation therapy, administered before radiation, and once daily on the day after each radiation therapy session (if no radiation planned that day) 1, 2
For most cancers, the standard premedication regimen includes oral dexamethasone 8 mg twice daily for 3 days (starting 1 day before docetaxel), as recommended by the American Society of Clinical Oncology 3

For patients receiving highly emetogenic chemotherapy, dexamethasone should be part of a multi-drug regimen including 5-HT3 receptor antagonists and/or NK1 receptor antagonists, according to the National Comprehensive Cancer Network guidelines 1, 2
For low-emetic risk radiation therapy to head and neck, dexamethasone can be used as rescue therapy rather than prophylaxis, as suggested by the American College of Radiology 2

If the patient is receiving immunotherapy, it is essential to discuss with the oncologist, as corticosteroids may potentially attenuate immunotherapy benefits, according to the Society for Immunotherapy of Cancer 1
Patients on dexamethasone should be monitored for hyperglycemia, especially those with diabetes, as well as mood changes, insomnia, and other neuropsychiatric effects, as recommended by the Endocrine Society 1